Kolexia
Lok Anne Oncologie hémato.
Lok Anne
Oncologie hémato.
Hôpital Hôtel-Dieu Nantes
Nantes, France
78 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Myélome multiple Leucémies Leucémie aigüe myéloïde Lymphome B Leucémie myéloïde COVID-19 Hémopathies Leucémie chronique lymphocytaire à cellules B

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Blin Nicolas
Blin Nicolas
Hôpital Hôtel-Dieu Nantes, Nantes, France
Mahe Beatrice
Mahe Beatrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Dubruille Viviane
Dubruille Viviane
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Janssen
15 collaboration(s)
Dernière en 2023
Abbvie
11 collaboration(s)
Dernière en 2023
AstraZeneca
9 collaboration(s)
Dernière en 2023
MundiPharma
1 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN-CLL-314: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
American journal of hematology   02 janvier 2024
Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience
65th ASH Annual Meeting Abstracts   02 novembre 2023
HILDEGAZ: Phase 1 Dose Escalation of Early Infusion of Zoledronic Acid in Combination With Increasing Low-dose of Interleukin-2 in Order to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allogeneic Stem Cell Transplantation (SCT)
Essai Clinique (CHU Nantes)   05 octobre 2023
LAMSA2020: A Phase II Randomized Study to Assess the Efficacy on Outcome of Venetoclax Combined With Cytarabine Versus Idarubicin Combined With Cytarabine Administered as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission
Essai Clinique (French Innovative Leukemia Organisation)   07 septembre 2023
Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma
Annual Meeting Abstracts 2022   15 novembre 2022
Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
Annual Meeting Abstracts 2022   15 novembre 2022
KinHémo: Physical Fitness Impact of Early Physiotherapy Intervention With a Standardized Exercise Therapy Program in Adult Patients Receiving Intensive Induction Chemotherapy for Treatment of Acute Leukemia During Extended Hospitalization. Randomized Controlled Superiority Trial in Parallel Arms, Multicentric (KinHémo)
Essai Clinique (CHU Angers)   02 novembre 2022
B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Transplantation and cellular therapy   24 février 2022